Do analysts recommend BLUW or PLX?

Protalix BioTherapeutics has a consensus target price of $12.00, suggesting a potential upside of 421.74%. Given Protalix BioTherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Protalix BioTherapeutics is more favorable than Blue Water Acquisition Corp. III. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Blue Water Acquisition Corp. III 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Protalix BioTherapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has higher valuation and earnings, BLUW or PLX?

Protalix BioTherapeutics has higher revenue and earnings than Blue Water Acquisition Corp. III. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Blue Water Acquisition Corp. III N/A N/A N/A N/A N/A Protalix BioTherapeutics $76.38M 2.43 $8.31M $0.18 12.78

Do analysts recommend BLUW or JATT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Blue Water Acquisition Corp. III 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 JATT Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings & valuation, BLUW or JATT?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Blue Water Acquisition Corp. III N/A N/A N/A N/A N/A JATT Acquisition N/A N/A $6.85M N/A N/A

Is BLUW or JATT more profitable?

Blue Water Acquisition Corp. III's return on equity of 0.00% beat JATT Acquisition's return on equity. Company Net Margins Return on Equity Return on Assets Blue Water Acquisition Corp. III N/A N/A N/A JATT Acquisition N/A -49.58% 2.84%

Do analysts prefer IZTC or BLUW?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Blue Water Acquisition Corp. III 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, IZTC or BLUW?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Invizyne Technologies N/A N/A N/A N/A N/A Blue Water Acquisition Corp. III N/A N/A N/A N/A N/A

Is IZTC or BLUW more profitable?

Company Net Margins Return on Equity Return on Assets Invizyne Technologies N/A N/A N/A Blue Water Acquisition Corp. III N/A N/A N/A

Do analysts rate BLUW or ALVR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Blue Water Acquisition Corp. III 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation & earnings, BLUW or ALVR?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Blue Water Acquisition Corp. III N/A N/A N/A N/A N/A AlloVir N/A N/A -$190.42M -$20.23 N/A

Is BLUW or ALVR more profitable?

Blue Water Acquisition Corp. III's return on equity of 0.00% beat AlloVir's return on equity. Company Net Margins Return on Equity Return on Assets Blue Water Acquisition Corp. III N/A N/A N/A AlloVir N/A -71.03% -61.27%

Do analysts recommend ZIVO or BLUW?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ZIVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Blue Water Acquisition Corp. III 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, ZIVO or BLUW?

Blue Water Acquisition Corp. III has lower revenue, but higher earnings than ZIVO Bioscience. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ZIVO Bioscience $15.85K 1,178.80 -$7.78M -$1.71 N/A Blue Water Acquisition Corp. III N/A N/A N/A N/A N/A

Is ZIVO or BLUW more profitable?

Company Net Margins Return on Equity Return on Assets ZIVO Bioscience N/A N/A -2,240.92% Blue Water Acquisition Corp. III N/A N/A N/A

Blue Water Acquisition Corp. III (BLUW) Competitors

$10.32 +0.01 (+0.10%)

As of 06/26/2026 03:59 PM Eastern

Compare

BLUW vs. PLX, JATT, IZTC, ALVR, and ZIVO

Should you buy Blue Water Acquisition Corp. III stock or one of its competitors? MarketBeat compares Blue Water Acquisition Corp. III with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Blue Water Acquisition Corp. III include Protalix BioTherapeutics (PLX), JATT Acquisition (JATT), Invizyne Technologies (IZTC), AlloVir (ALVR), and ZIVO Bioscience (ZIVO). These companies are all part of the "medical" sector.

How does Blue Water Acquisition Corp. III compare to Protalix BioTherapeutics?

Blue Water Acquisition Corp. III (NASDAQ:BLUW) and Protalix BioTherapeutics (NYSE:PLX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings.

Protalix BioTherapeutics has higher revenue and earnings than Blue Water Acquisition Corp. III.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Blue Water Acquisition Corp. III	N/A	N/A	N/A	N/A	N/A
Protalix BioTherapeutics	$76.38M	2.43	$8.31M	$0.18	12.78

In the previous week, Blue Water Acquisition Corp. III had 1 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 2 mentions for Blue Water Acquisition Corp. III and 1 mentions for Protalix BioTherapeutics. Blue Water Acquisition Corp. III's average media sentiment score of 0.43 beat Protalix BioTherapeutics' score of 0.00 indicating that Blue Water Acquisition Corp. III is being referred to more favorably in the media.

Company	Overall Sentiment
Blue Water Acquisition Corp. III	Neutral
Protalix BioTherapeutics	Neutral

16.5% of Protalix BioTherapeutics shares are owned by institutional investors. 6.7% of Protalix BioTherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Blue Water Acquisition Corp. III has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. Blue Water Acquisition Corp. III's return on equity of 0.00% beat Protalix BioTherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Blue Water Acquisition Corp. III	N/A	N/A	N/A
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%

Protalix BioTherapeutics has a consensus target price of $12.00, suggesting a potential upside of 421.74%. Given Protalix BioTherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Protalix BioTherapeutics is more favorable than Blue Water Acquisition Corp. III.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Blue Water Acquisition Corp. III	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Protalix BioTherapeutics beats Blue Water Acquisition Corp. III on 6 of the 11 factors compared between the two stocks.

How does Blue Water Acquisition Corp. III compare to JATT Acquisition?

Blue Water Acquisition Corp. III (NASDAQ:BLUW) and JATT Acquisition (NYSE:JATT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, media sentiment, dividends, institutional ownership and earnings.

In the previous week, Blue Water Acquisition Corp. III had 2 more articles in the media than JATT Acquisition. MarketBeat recorded 2 mentions for Blue Water Acquisition Corp. III and 0 mentions for JATT Acquisition. Blue Water Acquisition Corp. III's average media sentiment score of 0.43 beat JATT Acquisition's score of 0.00 indicating that Blue Water Acquisition Corp. III is being referred to more favorably in the media.

Company	Overall Sentiment
Blue Water Acquisition Corp. III	Neutral
JATT Acquisition	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Blue Water Acquisition Corp. III	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
JATT Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Blue Water Acquisition Corp. III	N/A	N/A	N/A	N/A	N/A
JATT Acquisition	N/A	N/A	$6.85M	N/A	N/A

Blue Water Acquisition Corp. III's return on equity of 0.00% beat JATT Acquisition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Blue Water Acquisition Corp. III	N/A	N/A	N/A
JATT Acquisition	N/A	-49.58%	2.84%

48.0% of JATT Acquisition shares are owned by institutional investors. 20.0% of JATT Acquisition shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Blue Water Acquisition Corp. III beats JATT Acquisition on 4 of the 7 factors compared between the two stocks.

How does Blue Water Acquisition Corp. III compare to Invizyne Technologies?

Invizyne Technologies (NASDAQ:IZTC) and Blue Water Acquisition Corp. III (NASDAQ:BLUW) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, media sentiment, valuation, risk and institutional ownership.

Company	Net Margins	Return on Equity	Return on Assets
Invizyne Technologies	N/A	N/A	N/A
Blue Water Acquisition Corp. III	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invizyne Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Blue Water Acquisition Corp. III	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Blue Water Acquisition Corp. III had 2 more articles in the media than Invizyne Technologies. MarketBeat recorded 2 mentions for Blue Water Acquisition Corp. III and 0 mentions for Invizyne Technologies. Blue Water Acquisition Corp. III's average media sentiment score of 0.43 beat Invizyne Technologies' score of 0.00 indicating that Blue Water Acquisition Corp. III is being referred to more favorably in the news media.

Company	Overall Sentiment
Invizyne Technologies	Neutral
Blue Water Acquisition Corp. III	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invizyne Technologies	N/A	N/A	N/A	N/A	N/A
Blue Water Acquisition Corp. III	N/A	N/A	N/A	N/A	N/A

Summary

Blue Water Acquisition Corp. III beats Invizyne Technologies on 3 of the 3 factors compared between the two stocks.

How does Blue Water Acquisition Corp. III compare to AlloVir?

Blue Water Acquisition Corp. III (NASDAQ:BLUW) and AlloVir (NASDAQ:ALVR) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, media sentiment, profitability, dividends, earnings and analyst recommendations.

Blue Water Acquisition Corp. III's return on equity of 0.00% beat AlloVir's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Blue Water Acquisition Corp. III	N/A	N/A	N/A
AlloVir	N/A	-71.03%	-61.27%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Blue Water Acquisition Corp. III	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Blue Water Acquisition Corp. III had 2 more articles in the media than AlloVir. MarketBeat recorded 2 mentions for Blue Water Acquisition Corp. III and 0 mentions for AlloVir. Blue Water Acquisition Corp. III's average media sentiment score of 0.43 beat AlloVir's score of 0.00 indicating that Blue Water Acquisition Corp. III is being referred to more favorably in the media.

Company	Overall Sentiment
Blue Water Acquisition Corp. III	Neutral
AlloVir	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Blue Water Acquisition Corp. III	N/A	N/A	N/A	N/A	N/A
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A

66.1% of AlloVir shares are owned by institutional investors. 32.1% of AlloVir shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Blue Water Acquisition Corp. III beats AlloVir on 5 of the 7 factors compared between the two stocks.

How does Blue Water Acquisition Corp. III compare to ZIVO Bioscience?

ZIVO Bioscience (NASDAQ:ZIVO) and Blue Water Acquisition Corp. III (NASDAQ:BLUW) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership.

In the previous week, Blue Water Acquisition Corp. III had 1 more articles in the media than ZIVO Bioscience. MarketBeat recorded 2 mentions for Blue Water Acquisition Corp. III and 1 mentions for ZIVO Bioscience. Blue Water Acquisition Corp. III's average media sentiment score of 0.43 beat ZIVO Bioscience's score of 0.00 indicating that Blue Water Acquisition Corp. III is being referred to more favorably in the news media.

Company	Overall Sentiment
ZIVO Bioscience	Neutral
Blue Water Acquisition Corp. III	Neutral

Company	Net Margins	Return on Equity	Return on Assets
ZIVO Bioscience	N/A	N/A	-2,240.92%
Blue Water Acquisition Corp. III	N/A	N/A	N/A

Blue Water Acquisition Corp. III has lower revenue, but higher earnings than ZIVO Bioscience.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ZIVO Bioscience	$15.85K	1,178.80	-$7.78M	-$1.71	N/A
Blue Water Acquisition Corp. III	N/A	N/A	N/A	N/A	N/A

12.8% of ZIVO Bioscience shares are owned by institutional investors. 48.9% of ZIVO Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Blue Water Acquisition Corp. III	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Blue Water Acquisition Corp. III beats ZIVO Bioscience on 4 of the 7 factors compared between the two stocks.

Get Blue Water Acquisition Corp. III News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BLUW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BLUW vs. The Competition

Export

Metric	Blue Water Acquisition Corp. III	Biological Products, Except Diagnostic Industry	Medical Sector	NASDAQ Exchange
Market Cap	$290.48M	$352.18M	$6.70B	$12.22B
Dividend Yield	N/A	N/A	2.67%	6.13%
P/E Ratio	N/A	N/A	25.79	24.18
Price / Sales	N/A	207.00	560.49	109.71
Price / Cash	N/A	22.44	46.99	54.37
Price / Book	N/A	4.85	10.77	6.35
Net Income	N/A	-$141.03M	$3.57B	$337.74M
7 Day Performance	N/A	1.25%	2.18%	0.09%
1 Month Performance	0.44%	-3.52%	1.09%	-0.13%
1 Year Performance	7.17%	63.99%	34.22%	27.58%

Blue Water Acquisition Corp. III Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BLUW Blue Water Acquisition Corp. III	N/A	$10.32 +0.1%	N/A	+7.2%	$290.48M	N/A	N/A	2	Short Interest Increase
PLX Protalix BioTherapeutics	2.6055 of 5 stars	$2.22 flat	$12.00 +440.5%	+58.6%	$178.87M	$76.38M	N/A	200	News Coverage Gap Down
JATT JATT Acquisition	N/A	$10.68 -0.7%	N/A	+784.3%	$86.27M	N/A	N/A	3	Gap Down
IZTC Invizyne Technologies	N/A	$7.83 +23.7%	N/A	-27.7%	$48.95M	N/A	N/A	29	Gap Up
ALVR AlloVir	N/A	$4.72 +3.7%	N/A	+65.4%	$23.80M	N/A	N/A	110	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BLUW) was last updated on 6/27/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blue Water Acquisition Corp. III (BLUW) Competitors

BLUW vs. PLX, JATT, IZTC, ALVR, and ZIVO

How does Blue Water Acquisition Corp. III compare to Protalix BioTherapeutics?

Summary

How does Blue Water Acquisition Corp. III compare to JATT Acquisition?

Summary

How does Blue Water Acquisition Corp. III compare to Invizyne Technologies?

Summary

How does Blue Water Acquisition Corp. III compare to AlloVir?

Summary

How does Blue Water Acquisition Corp. III compare to ZIVO Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLUW vs. The Competition

Blue Water Acquisition Corp. III Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Blue Water Acquisition Corp. III (BLUW) Competitors

BLUW vs. PLX, JATT, IZTC, ALVR, and ZIVO

How does Blue Water Acquisition Corp. III compare to Protalix BioTherapeutics?

Which has higher valuation and earnings, BLUW or PLX?

Does the media refer more to BLUW or PLX?

Do institutionals and insiders hold more shares of BLUW or PLX?

Is BLUW or PLX more profitable?

Do analysts recommend BLUW or PLX?

Summary

How does Blue Water Acquisition Corp. III compare to JATT Acquisition?

Does the media refer more to BLUW or JATT?

Do analysts recommend BLUW or JATT?

Which has preferable earnings & valuation, BLUW or JATT?

Is BLUW or JATT more profitable?

Do insiders and institutionals hold more shares of BLUW or JATT?

Summary

How does Blue Water Acquisition Corp. III compare to Invizyne Technologies?

Is IZTC or BLUW more profitable?

Do analysts prefer IZTC or BLUW?

Does the media refer more to IZTC or BLUW?

Which has preferable earnings and valuation, IZTC or BLUW?

Summary

How does Blue Water Acquisition Corp. III compare to AlloVir?

Is BLUW or ALVR more profitable?

Do analysts rate BLUW or ALVR?

Does the media favor BLUW or ALVR?

Which has better valuation & earnings, BLUW or ALVR?

Do institutionals & insiders hold more shares of BLUW or ALVR?

Summary

How does Blue Water Acquisition Corp. III compare to ZIVO Bioscience?

Does the media refer more to ZIVO or BLUW?

Is ZIVO or BLUW more profitable?

Which has stronger earnings & valuation, ZIVO or BLUW?

Do insiders & institutionals hold more shares of ZIVO or BLUW?

Do analysts recommend ZIVO or BLUW?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLUW vs. The Competition

Blue Water Acquisition Corp. III Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools